Molecular pathogenesis of preeclampsia:  microRNA hypothesis by Andalas, Mohd. et al.
Proceedings of The Annual International Conference Syiah Kuala University 2011 
Banda Aceh, Indonesia. November 29-30, 2011 
Volume 1 Number 1, 2011 
156
Molecular pathogenesis of preeclampsia:  
microRNA hypothesis  
 
Mohd. Andalas1, Harapan1, Diky Mudhakir2, Muhammad Ichsan3, Natalia C. 
Pedroza4 and Saurabh Laddha5 
 
1Obstetrics and Gynecology Department, School of Medicine Syiah Kuala University, Banda 
Aceh – Indonesia; 2Schools of Pharmacy, Bandung Technology Institute, Bandung – 
Indonesia; 3Molecular Biology Department, School of Medicine Syiah Kuala University, 
Banda Aceh – Indonesia / Institutes of Microbiology, Universitatsmedizin Gottingen Georg-
August-University, Gottingen – Germany; 4Viral Vector Core and Gene Therapy, 
Neuroscience Group, University Research Center, University of Antioquia, Medellín – 
Colombia; 5 Non-coding RNAs Informatics, Institute of Genomics and Integrative Biology, 
Delhi – India. Corresponding author:harapantumangger@yahoo.com 
 
Abstract. The discovery of micro RNA (miRNA) in 1993 by Ambros and colleagues has a huge influence in 
pathogenesis theory, diagnosis and treatment approach of some diseases. Some studies have conducted to seek 
the association alterations of miRNA expression to incidences and severity of preeclampsia (PE). We have reviewed 
some studies that conducted to seek the association of miRNA and PE and we discussed the role of various miRNAs 
in PE pathogenesis. In summary, we have shown that many researchers have given evident that the different 
placental and plasma miRNA expression is associated with PE. Some studies also identified the novel candidate of 
miRNAs (and their pathways) that may be of etiologic relevance in the pathogenesis of PE. Base on review, specific 
miRNA have a role to down regulate of anti apoptosis genes, regulate angiogenics growth factors such as 
angiogenin, vascular endothelial growth factor (VEGF) B (VEGF-β), cysteine-rich 61 (CYR61), Placental growth 
factor (PlGF) and VEGF-A that have a role in angiogenesis. miRNA also have a role in  survival, migration, and 
capillary tube formation of HUVEC by targeted of c-kit. Some miRNAs target genes that participate in immunologic 
dysfunction, cell adhesion, cell cycle, and signaling. miRNA also have a roles in endothelial cell response to 
hypoxia, cell differentiation, and survival. A miRNA influence calcium signaling through negative regulations of the 
calmodulin-coding mRNAs, Mef2a and Gata4, mainly in smooth muscle cells that contribute to PE pathogenesis. 
These investigations provide novel targets for further investigation of the pathogenesis of PE and these differential 
miRNAs may be potential markers for the diagnosis and provide a potential therapeutic target for PE. Further 
investigations on posttranscriptional regulation in PE to evaluate biologic effects of identified miRNAs (including 
confirmations of miRNA and target gene interactions) are needed. 
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Introduction  
Preeclampsia (PE) is a disease of pregnancy characterized by hypertension (defined as 
systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) and 
proteinuria (300 mg or greater in a 24-h urine specimen and/or protein to creatinine ratio 
of > 0.30), developing after 20 weeks of gestation (Sibai et al., 2005). It has been 
estimated that PE affects 3%–5% of pregnancies worldwide, recently, it has been reported 
that PE complicates 3-8% of pregnancies (Duley, 2009; WHO, 2005). There is much 
evidence shown that PE originates in the placenta and thus the placenta is believed as the 
central basis to the pathogenesis of PE (Young et al., 2010). But the molecular basis for 
placental dysregulation of these pathogenic factors remains unknown.   
Many hypotheses have emerged that attempt together a causal framework for the 
disease, causing PE to be named the ‘disease of theories’ (Cerdeira & Karumanchi, 2010). 
Here, we hypothesize that microRNA has a main role in PE patoghenesis: microRNA 
hypothesis. MicroRNAs (miRNAs) are small, non coding RNAs ~22 nucleotides  (nt) in length 
that regulate gene expression with important functions in the regulation of a variety of 
biological processes involved in development, cell differentiation, regulation of cell cycle, 
metabolism and  apoptosis (Bushati & Cohen, 2007; Garzon et al., 2009). Albeit only 1% of 
the genomic transcripts in mammalian cells encode miRNA, miRNAs are predicted to control 
the activity of more than 60% of all protein-coding genes (Friedman et al., 2009; Sun et 
al., 2010). It has been estimated that miRNAs regulate ~30% of human genes (Bartel, 
2004). MicroRNAs regulate mRNA, which encodes proteins that modulate cellular functions, 
therefore, miRNAs play important roles in physiological homeostasis in health and 
pathophysiological derangement in disease (Sun et al., 2010). MicroRNAs are known to 
have function in pathological process and prognosis of diseases such as diabetes (Poy et al., 
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2004), neurodegenerative disorder (Jin et al., 2004), gastrointestinal diseases (Pellish et 
al., 2008) and cancer and its resistant for chemotherapy  (Garofalo & Croce, 2011). Certain 
miRNAs are tissue-specific and the temporal expression of the tissue-specific miRNAs 
correlates closely with the specific physiological or pathological status of the corresponding 
organs (Sun et al., 2010).  
Functional studies indicate that miRNAs participate in the regulation of almost every 
cellular process investigated so far and that changes in their expression are associated with 
many human pathologies (Krol et al., 2010). Some scientifically proven theories have been 
proposed to seek the association of alterations of miRNA expression to incidences and 
severity of preeclampsia (PE). Research conducted by Pineles et al. (2007) shows that PE is 
associated with alterations in placental miRNA expression. This research reported that miR-
210 and -182 are expressed differentially in the human placentas of patients with PE 
compared with control subjects. In this review we explore the result of such investigations 
that discuss the association of miRNA and PE along with the role of various mRNAs in PE 
pathogenesis.  
 
Biogenesis and Mechanism Action of miRNA 
MicroRNAs are processed from RNA polymerase II (RNAPII)-specific transcripts of 
independent genes or from introns of protein-coding genes (Carthew & Sontheimer, 2009). 
These initial miRNA precursors, known as pri-miRNAs, are processed into ~70 nt hairpin 
structures known as pre-miRNAs - in the nucleus - by a nuclear enzyme complex known as 
the microprocessor that contains an endoribonuclease - Drosha - and a double-stranded 
RNA binding protein - DiGeorge syndrome critical region 8 (DGCR8). This process called as 
Drosha–DGCR8 step (Fabian et al., 2010a; Krol et al., 2010). Drosha is an RNase III 
enzyme which contains two RNase domains  which cleave the 5` and 3` ends, releasing the 
pre-miRNA (Fabian et al., 2010b).  
The pre-miRNA is exported from the nucleus to the cytoplasm by Exportin-5 (XPO5) 
(Yi et al., 2003).  In the cytoplasm, the pre-miRNA is further cleaved by another RNase III 
enzyme – Dicer, which removes the loop to yield the ~22 nucleotide miRNA duplext (Sun et 
at., 2010). After being unwound by a helicase, one strand of miRNA is destined to be the 
mature miRNA called as guide strand and the complementary strand - called as passenger 
strand or miRNA* - is rapidly degraded (Sun et al., 2010). The thermodynamic stability of 
the miRNA duplex termini and the identity of the nucleotides in the 3′ overhang determine 
which strands act as guide strand (Ryan et al., 2010). Then the guide strand is incorporated 
into a miRNA-induced silencing complex (miRISC) (Bartel, 2004), see Figure 1.  
Guided by the sequence complementarity between the small RNA and the target 
mRNA, miRNA-RISC-mediated gene inhibition is commonly divided into three processes: (a) 
site-specific cleavage, (b) enhanced mRNA degradation and (c) translational inhibition (Gu 
& Kay, 2010). The miRISC-mRNA interaction can lead to several modes of direct and 
indirect on translational repression (Sun et al., 2010). Direct on translational repression 
involved: (a). Initiation block: The miRISC inhibits translation initiation by interfering with 
eIF4F-cap recognition and 40S small ribosomal subunit recruitment or by antagonizing 60S 
subunit joining and preventing 80S ribosomal complex formation. (b) Postinitiation block: 
premature ribosomal drop-off, the 40S/60S ribosomes are dissociated from mRNA, stalled 
or slowed elongation, the 40S/60S ribosomes are prohibited from joining during the 
elongation process or facilitating proteolysis of nascent polypeptides (Fabian et al., 2010b; 
Nilsen, 2007; Sun et al., 2010).  
The indirect on translational repression occurs via mRNA deadenylation and 
degradation (Nilsen, 2007; Sun et al., 2010). Deadenylation of mRNAs is mediated by 
glycine-tryptophan protein of 182 kDa (GW182) proteins - the components of miRISC, 
poly(A)-binding  protein (PABP), and Argonaute (AGO) protein (Fabian et al., 2010b; Gu & 
Kay, 2010; Krol et al., 2010). Argonaute (AGO) proteins are core components of the 
miRISC which are directly associated with miRNAs (Krol et al., 2010). Then this molecule 
will interacts with the CCR4/CAF1 deadenylase complex to facilitate deadenylation of the 
poly(A) tail (Fabian et al., 2010b; Krol et al., 2010). Following deadenylation, the 5`-
terminal cap is removed by the  decapping enzyme - decapping DCP1-DCP2 complex 
(Fabian et al., 2010b). Endonucleolytic cleavage and mRNA degradation that  miRNA-
mediated by AGO2 (Ender & Meister, 2010; Krol et al., 2010).  
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Figure 1. Pathways of microRNA (miRNA) biogenesis and action (Lee & Dutta, 2009). 
Abbreviations: miRNP, ribonucleoprotein complex containing miRNA; ORF, open reading 
frame; P-body, PACT, interferon-inducible double-stranded RNA-dependent activator; RISC, 
RNA-induced silencing complex; TRBP, human immunodeficiency virus–transactivating 
RNA-binding protein; UTR, untranslated region of mRNA. 
 
Molecular Mechanisms of Preeclampsia  
Angiogenic factor such as placental growth factor (PlGF) and vascular endothelial growth 
factor (VEGF) and their receptors Flt1 [also known as vascular endothelial growth factor 
receptor 1 (VEGFR-1)], VEGFR-2, Tie-1, and Tie-2, are essential for normal placental 
vascular development (Young et al., 2010). Alterations in the regulation and signaling of 
angiogenic pathways in early gestation contribute to the inadequate cytotrophoblast 
invasion seen in preeclampsia (Young et al., 2010). Additionally, perturbation of the renin–
aldosterone–angiotensin II axis, excessive oxidative stress, inflammation, immune 
maladaptation, and genetic susceptibility may all contribute to the pathogenesis of 
preeclampsia (Young et al., 2010). 
Several placentally derived ‘‘toxins’’ were suggested, including cytokines, anti-
angiogenic factors, syncytiotrophoblast microparticles (STBM), and formed blood products 
activated in the intervillus space (Roberts & Hubel, 2009). The role of these anti-angiogenic 
factors such as soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) in 
early placental vascular development and in trophoblast invasion is just the beginning to be 
explored in placental dysregulation. Hypoxia is likely to be an important regulator (Young et 
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al., 2010). Oxidative stress was an attractive component as part of the linkage 
(Mellembakken et al., 2002). Reactive oxygen species could be generated by the reduced 
perfusion of the placenta with consequent activation of monocytes and neutrophils passing 
through the intervillus space. Oxidative stress would also stimulate release of cytokines, 
antiangiogenic factors, microparticles and other potential linkers (Roberts & Hubel, 2009).   
Some factors such as genetic factors, oxidative stress, catechol-O-methyltransferase 
(COMT) deficiency, hemoxygenase deficiency and immunological/inflammatory factors 
cause placental dysfunction which leads angiogenic imbalance, increase sFlt1 and sEng, 
decrease of PlGF and VEGF (Maynard et al., 2008; Mutter & Karumanchi, 2008; Young et 
al., 2010). sFlt1 and sEng levels have been shown to be elevated in the serum of 
preeclamptic women, as compared to normal preganant women, weeks before the 
appearance of overt clinical manifestations of the disease (Levine et al., 2004, 2006). 
Compared to normo-tensive controls, in patients with severe preeclampsia, free PlGF and 
VEGF levels are significantly declined and sFlt1 levels are significantly elevated (Levine et 
al., 2004, 2006).  
It`s clear that the increase of sFlt1 expression associated with decreased PlGF and 
VEGF signaling, cause inadequate placental vascular development (Levine et al., 2004; 
Maynard et al., 2003; Venkatesha et al., 2006). This alterations causes widespread 
endothelial dysfunction that results in hypertension, proteinuria, and other systemic 
manifestations of preeclampsia (Maynard et al., 2003; Mutter & Karumanchi, 2008).  
 
The Role of miRNA in Preeclampsia Pathogenesis 
The first research that linked miRNA and PE was conducted by Pineles et al. (2007) The 
study was performed to determine whether PE and small-for-gestational age (SGA) are 
associated with alterations in placental miRNA expression. Thus they evaluated placental 
miRNAs expression from patients with PE, SGA, PE + SGA along with a control group. They 
found that seven miRNAs (miR-210, miR-155, miR-181b, miR-182*, miR-200b, miR-154*, 
and miR-183) were significantly higher expressed between PE+SGA and the control group.  
The expression of miR-182 and miR-210 was significantly higher in PE than in the control 
group. Based on Gene Ontology (GO) analysis, miR-182 have a role to down-regulate anti-
apoptosis genes. They speculated that high expression of miR-182 in PE may contribute to 
the increased apoptosis in the placentas of patients with preeclampsia. The targets of both 
miR-182 and miR-210 are enriched in immune processes, which support the association 
between abnormal immune responses and PE as descripted previously by Kim et al. (2005) 
Beside that, angiogenin and VEGF-β are potential targets of miR-182 and miR-182*, 
respectively (Pineles et al.,2007). These molecules have a role in angiogenesis. A study by   
et al.(2005) elucidates miRNA essentiality,  that in mice with deficient miRNA, defective 
angiogenesis is caused that leads to embryonic lethality. 
A study with small sample in China found expression of miR-130a, miR-181a, miR-
222, miR-16, miR-26b, miR-29b and miR-195 in placenta of severe PE women (Fei et al., 
2009). The other reseacrh by Hu et al. (2009) reported that miR-16, miR-29b, miR-195, 
miR-26b, miR-181a, miR-335 and miR-222 were significantly increased in placenta from 
women with severe PE. This research revealed that some angiogenic growth factors were 
potential targets of the altered miRNA, such as cysteine-rich 61 (CYR61), PlGF, VEGF-A 
which were targets of miR-222, miR-335 and miR-195, respectively.  It describes the role 
of this angiogenics factors for the development of PE. It is well known that the expressions 
of  VEGF-A and VEGF receptor-1 are down-regulated in cytotrophoblasts of PE placenta 
(Mutter & Karumanchi, 2008; Zhou et al., 2002). Several articles reviewed by Lam et al. 
(2005) provides sufficient evidenence that PlGF is also dysregulated in serum or placental 
tissue of women with PE.  
The research by Mo et al. (2002) found that CYR61 is essential for placental 
development and vascular integrity. Gellhaus et al. (2006) found that CYR61 is significantly 
decreased in PE placenta. CYR61 is a secreted matrix protein expressed by nearly all types 
of vascular cells and trophoblasts and implicated in diverse cellular processes such as 
proliferation, migration, differentiation, and adhesion.  It was found that the expression of 
CYR61 in human placenta was significantly lower than that of the normal control.46 
Recently, study reported that overexpression of miR-155 contributes to PE development by 
targeting and down-regulating angiogenic regulating factor CYR61 (Zhang et al., 2010). It 
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was also reported that CYR61 has been demonstrated to be one of the important early 
angiogenic factors during pregnancy, this role is probably because CYR61 can induce the 
expression of VEGF (Zhang et al., 2010). 
Poliseno  et al. (2006) found that overexpression of  miR-221/222  inhibits tube 
formation, migration, and wound healing in response to stem cell factor in human umbilical 
endothelial cells (HUVEC). This effect, arises because c-kit is a target of miR-221/222.  c-kit 
is a tyrosine kinase receptor for stem cell factor and has been shown to promote survival, 
migration, and capillary tube formation HUVEC (Matsui et al., 2004).  
 The other study by Zhu et al. (2009) was conducted in China population. They 
investigated that 34 miRNAs were expressed differentially in PE placentas, compared to 
normal placentas. Of these, 11 microRNAs were over-expressed, and 23 miRNAs were 
under-expressed in PE placentas. miR-518b showed significant overexpression in severe PE 
vs control; miR-18a, -363, and -542-3p were significantly underexpressed in severe PE vs 
control. miR-152 showed significant overexpression in mild PE vs control specimens and in 
severe PE vs control specimens. miR-411 and miR-377 were under-expressed in mild PE vs 
control specimens and in severe PE vs control. Zhu et al. (2009) also found that miR-210 
was significantly underexpressed in mild PE vs the other 2 groups; while significant 
overexpression was found in severe PE vs all other groups. In their comments, they 
mention that the increase in miR-210 expression in sPE induced by focal regions of 
ischemia/hypoxia in placentas is cause of poor placentation in PE pregnancies, as previous 
study showed that the expression of miR-210 was increased on exposure to hypoxia 
(Fasanaro et al., 2008). They speculated that the decrease of miR-210 in mPE as a 
compensatory mechanism in the pregnancies with mPE, but there isn`t a sufficient 
explanation.  
Recently, Enquobahrie et al. (2011) found that eight miRNAs were differentially 
expressed (miR-210 up-regulated and 7 - miR-328, miR-584, miR-139-5p, miR-500, miR-
1247, miR-34C-5p and miR-1-down-regulated) among PE cases compared with controls. 
These miRNAs target genes that participate in organ/system development (cardiovascular 
and reproductive system), immunologic dysfunction, cell adhesion, cell cycle, and signaling. 
In their comment consistent with the other scientist, they stated that miR-210 plays roles 
in endothelial cell response to hypoxia, formation of capillary-like structures, vascular 
endothelial growth factor– driven cell migration, cell differentiation, and survival, events 
that are integral to preeclampsia pathogenesis. Enquobahrie et al. (2011) utilizing the 
results of previous study conducted by Ikeda et al. (2009) speculated that miR-1 influence 
risk of PE through its effect on calcium signaling. They demonstrated that miR-1 influence 
calcium signaling through negative regulations of the calmodulin-coding mRNAs, Mef2a and 
Gata4, mainly in smooth muscle cells. It`s believed that PE has associated with abnormal 
calcium metabolism and related consequences (Thway et al., 2004). 
The association between PE and altered miRNA expression suggests the possibility of 
a functional role for miRNA in this disease.  These different miRNAs may play an important 
role in pathogenesis of PE and may become diagnostic markers and therapeutic target for 
PE. 
  
Conclusion 
In summary, we have shown that there are many scientific evidences that have proven the 
fact that the differential placental and plasma miRNA expression is associated with PE. 
Some researches also identify novel candidate miRNAs (and pathways they regulate) that 
may be of etiologic relevance in the pathogenesis of PE.  It provides novel targets for 
further investigation of the pathogenesis of PE and these differential miRNAs may be 
potential markers for the diagnosis and provide a potential therapeutic target for PE. 
Further investigations on posttranscriptional regulation in PE to evaluate biologic effects of 
identified miRNAs (including confirmations of miRNA and target gene interactions) are 
needed.     
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